Form 4: Immunome CFO Max Rosett Trades Shares

Immunome Inc. Chief Financial Officer Max Rosett reported transactions involving company common stock and stock options on April 2, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Max Rosett, Chief Financial Officer of Immunome Inc., engaged in several transactions involving the company's common stock and stock options on April 2, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on December 26, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• Rosett acquired 31,848 shares of common stock at $1.05 per share and an additional 39,713 shares at $1.35 per share.
• Concurrently, Rosett disposed of 63,656 shares at a weighted average price of $21.91 (ranging from $21.44 to $22.44) and 1,344 shares at a weighted average price of $22.48 (ranging from $22.45 to $22.56).
• Following these transactions, Rosett beneficially owns 55,381 shares directly and 54,037 shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the significant sale of shares by a key executive, despite being executed under a 10b5-1 plan. While the plan itself is a neutral compliance tool, the act of selling a large volume can be perceived negatively by the market.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to stock transactions, which can provide a degree of transparency and compliance.
• The acquisition of shares at lower prices ($1.05 and $1.35) could be viewed positively if these represent new grants or purchases at a favorable valuation point, though the context of these acquisitions is not fully detailed beyond being linked to vested options.
• The CFO's continued involvement and transactions, even if sales, demonstrate ongoing engagement with the company's stock.

Negatives

• The disposal of a significant number of shares (63,656 + 1,344 = 65,000 shares) at prices substantially higher than the acquisition prices of other shares ($21.91 and $22.48) suggests a profit-taking event.
• The disparity between the acquisition prices of some shares and the sale prices could indicate a significant difference in valuation or timing, potentially raising questions about the CFO's perception of the stock's immediate future value.

Risks

• The sale of a substantial number of shares by a key executive could be interpreted by the market as a lack of confidence in the company's short-term prospects, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the timing and volume of sales could still lead to scrutiny or negative perception if not clearly understood within the context of the plan's parameters and the executive's overall holdings.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It solely reports on past transactions executed under a pre-defined plan.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
• The weighted average purchase price for the transaction report was $21.91, and the range of prices were between $21.44 and $22.44, inclusive.
• The weighted average purchase price for the transaction report was $22.48, and the range of prices were between $22.45 and $22.56, inclusive.
• The option is fully vested.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of these trades under a Rule 10b5-1 plan is a common practice for executives to manage their stock holdings while adhering to regulations, particularly in the biotechnology sector where stock price can be volatile based on clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders: May perceive the CFO's sale of stock negatively, potentially leading to increased selling pressure or a decrease in confidence, despite the Rule 10b5-1 plan.
• Employees: May be influenced by the executive's stock transactions, potentially affecting morale or their own investment decisions.
• Management: The transactions are part of a structured plan, indicating adherence to governance protocols, but the volume of sales could still be a point of discussion internally.

Key Dates

Recommendation

The filing reports routine insider transactions under a Rule 10b5-1 plan, which is a standard compliance mechanism. While the sale of a significant number of shares by the CFO could be a short-term negative signal, the transactions were pre-planned and do not necessarily reflect a change in the executive's long-term view of the company's fundamentals. Without additional context on the company's performance or future prospects, a 'hold' recommendation is appropriate, suggesting investors monitor further developments.

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Common Stock, Rule 10b5-1, Beneficial Ownership, Immunome Inc., IMNM, Max Rosett, CFO Transactions